SGLT2 inhibitors and cirrhosis: A unique perspective on the comanagement of diabetes mellitus and ascites.
作者信息
Saffo Saad, Taddei Tamar
机构信息
Department of Internal Medicine Yale University School of Medicine New Haven CT.
Section of Digestive Diseases Yale University School of Medicine New Haven CT.
出版信息
Clin Liver Dis (Hoboken). 2018 Jul 26;11(6):141-144. doi: 10.1002/cld.714. eCollection 2018 Jun.
Abstract
摘要
相似文献
1
SGLT2 inhibitors and cirrhosis: A unique perspective on the comanagement of diabetes mellitus and ascites.钠-葡萄糖协同转运蛋白2抑制剂与肝硬化：糖尿病和腹水共同管理的独特视角
Clin Liver Dis (Hoboken). 2018 Jul 26;11(6):141-144. doi: 10.1002/cld.714. eCollection 2018 Jun.
2
Turning Foes to Friends: Knocking Down Diabetes Associated SGLT2 Transporters and Sustaining Life.化敌为友：攻克糖尿病相关的钠-葡萄糖协同转运蛋白2并维持生命
Curr Diabetes Rev. 2020;16(7):716-732. doi: 10.2174/1573399816666200117155016.
3
SGLT2 inhibitors: a promising new therapeutic option for treatment of type 2 diabetes mellitus.SGLT2 抑制剂：治疗 2 型糖尿病的有前途的新治疗选择。
J Pharm Pharmacol. 2013 Mar;65(3):317-27. doi: 10.1111/j.2042-7158.2012.01574.x. Epub 2012 Aug 9.
4
[Relative frequency of urinary tract infections in patients affected by diabetes mellitus type 2 treated with metformin and SGLT2 inhibitor. ].[使用二甲双胍和SGLT2抑制剂治疗的2型糖尿病患者尿路感染的相对频率。]
Orv Hetil. 2020 Mar;161(13):491-501. doi: 10.1556/650.2020.31690.
5
Update on SGLT2 Inhibitors-New Data Released at the American Diabetes Association.SGLT2抑制剂的最新进展——美国糖尿病协会发布的新数据
Crit Pathw Cardiol. 2017 Sep;16(3):93-95. doi: 10.1097/HPC.0000000000000125.
6
Safety of SGLT2 Inhibitors in Patients with Diabetes Mellitus.SGLT2抑制剂在糖尿病患者中的安全性。
Curr Drug Saf. 2019;14(2):87-93. doi: 10.2174/1574886314666190206164647.
7
Sodium glucose CoTransporter 2 (SGLT2) inhibitors: Current status and future perspective.钠-葡萄糖协同转运蛋白2（SGLT2）抑制剂：现状与未来展望
Eur J Pharm Sci. 2016 Oct 10;93:244-52. doi: 10.1016/j.ejps.2016.08.025. Epub 2016 Aug 12.
8
SGLT2 inhibitors to control glycemia in type 2 diabetes mellitus: a new approach to an old problem.SGLT2 抑制剂控制 2 型糖尿病患者的血糖：一个老问题的新方法。
Postgrad Med. 2014 Jan;126(1):111-7. doi: 10.3810/pgm.2014.01.2731.
9
Mechanisms of Protective Effects of SGLT2 Inhibitors in Cardiovascular Disease and Renal Dysfunction.SGLT2 抑制剂在心血管疾病和肾功能障碍中的保护作用机制。
Curr Top Med Chem. 2019;19(20):1818-1849. doi: 10.2174/1568026619666190828161409.
10
Effects of Sodium-glucose Cotransporter 2 Inhibitor Monotherapy on Weight Changes in Patients With Type 2 Diabetes Mellitus: a Bayesian Network Meta-analysis.钠-葡萄糖共转运蛋白 2 抑制剂单药治疗对 2 型糖尿病患者体重变化的影响：一项贝叶斯网状 Meta 分析。
Clin Ther. 2019 Feb;41(2):322-334.e11. doi: 10.1016/j.clinthera.2019.01.001. Epub 2019 Jan 30.
引用本文的文献
1
Complete Resolution of Refractory Ascites and Pleural Effusion with Sustained Improvement in Urinary Sodium Excretion in a Cirrhotic Patient Treated with Empagliflozin.恩格列净治疗的一名肝硬化患者难治性腹水和胸腔积液完全消退，尿钠排泄持续改善
J Clin Transl Hepatol. 2025 Aug 28;13(8):701-704. doi: 10.14218/JCTH.2025.00172. Epub 2025 Jun 19.
2
Therapeutic Potential of Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors in Liver Disease: Focus on Cirrhosis.钠-葡萄糖协同转运蛋白2（SGLT2）抑制剂在肝脏疾病中的治疗潜力：聚焦于肝硬化
Cureus. 2025 May 25;17(5):e84768. doi: 10.7759/cureus.84768. eCollection 2025 May.
3
Dapagliflozin and metabolic dysfunction-associated steatohepatitis.达格列净与代谢功能障碍相关脂肪性肝炎
BMJ. 2025 Jun 4;389:r1101. doi: 10.1136/bmj.r1101.
4
Safety and Efficacy of Dapagliflozin in Recurrent Ascites: A Pilot Study.达格列净治疗复发性腹水的安全性和有效性：一项试点研究。
Dig Dis Sci. 2025 Feb;70(2):835-842. doi: 10.1007/s10620-024-08667-4. Epub 2024 Oct 9.
5
Pharmacological Interventions for Cirrhotic Ascites: From Challenges to Emerging Therapeutic Horizons.肝硬化腹水的药物治疗：从挑战到新兴治疗领域。
Gut Liver. 2024 Nov 15;18(6):934-948. doi: 10.5009/gnl240038. Epub 2024 Aug 29.
6
Clinical Presentation, Pathological Spectrum, and Outcomes of Alcoholic Cirrhosis-Related Immunoglobulin A Nephropathy.酒精性肝硬化相关免疫球蛋白A肾病的临床表现、病理谱及预后
Kidney Int Rep. 2024 Feb 16;9(5):1369-1378. doi: 10.1016/j.ekir.2024.02.1397. eCollection 2024 May.
7
From liver to hormones: The endocrine consequences of cirrhosis.从肝脏到激素：肝硬化的内分泌后果。
World J Gastroenterol. 2024 Mar 7;30(9):1073-1095. doi: 10.3748/wjg.v30.i9.1073.
8
Reduced mortality and morbidity associated with metformin and SGLT2 inhibitor therapy in patients with type 2 diabetes mellitus and cirrhosis.二甲双胍和 SGLT2 抑制剂治疗 2 型糖尿病合并肝硬化患者的死亡率和发病率降低。
BMC Gastroenterol. 2023 Dec 19;23(1):450. doi: 10.1186/s12876-023-03085-8.
9
Innovative approaches to the management of ascites in cirrhosis.肝硬化腹水管理的创新方法。
JHEP Rep. 2023 Apr 5;5(7):100749. doi: 10.1016/j.jhepr.2023.100749. eCollection 2023 Jul.
10
Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors: Harms or Unexpected Benefits?钠-葡萄糖共转运蛋白 2（SGLT2）抑制剂：危害还是意外获益？
Medicina (Kaunas). 2023 Apr 10;59(4):742. doi: 10.3390/medicina59040742.
本文引用的文献
1
Sodium Glucose Cotransporter 2 Inhibitors in the Treatment of Diabetes Mellitus: Cardiovascular and Kidney Effects, Potential Mechanisms, and Clinical Applications.钠-葡萄糖协同转运蛋白2抑制剂在糖尿病治疗中的应用：心血管和肾脏效应、潜在机制及临床应用
Circulation. 2016 Sep 6;134(10):752-72. doi: 10.1161/CIRCULATIONAHA.116.021887. Epub 2016 Jul 28.
2
Heart failure outcomes with empagliflozin in patients with type 2 diabetes at high cardiovascular risk: results of the EMPA-REG OUTCOME® trial.恩格列净治疗心血管高危2型糖尿病患者的心力衰竭结局：EMPA-REG OUTCOME®试验结果
Eur Heart J. 2016 May 14;37(19):1526-34. doi: 10.1093/eurheartj/ehv728. Epub 2016 Jan 26.
3
The treatment of diabetes mellitus of patients with chronic liver disease.慢性肝病患者糖尿病的治疗。
Ann Hepatol. 2015 Nov-Dec;14(6):780-8. doi: 10.5604/16652681.1171746.
4
The mechanisms and therapeutic potential of SGLT2 inhibitors in diabetes mellitus.SGLT2 抑制剂在糖尿病中的作用机制及治疗潜力。
Annu Rev Med. 2015;66:255-70. doi: 10.1146/annurev-med-051013-110046. Epub 2014 Oct 17.
5
Safety profile of dapagliflozin for type 2 diabetes: pooled analysis of clinical studies for overall safety and rare events.达格列净用于2型糖尿病的安全性概况：总体安全性和罕见事件临床研究的汇总分析
Drug Saf. 2014 Oct;37(10):815-29. doi: 10.1007/s40264-014-0213-4.
6
Continuation of metformin use after a diagnosis of cirrhosis significantly improves survival of patients with diabetes.在诊断为肝硬化后继续使用二甲双胍可显著改善糖尿病患者的生存。
Hepatology. 2014 Dec;60(6):2008-16. doi: 10.1002/hep.27199. Epub 2014 Jul 31.
7
The emerging role of insulin and insulin-like growth factor signaling in cancer stem cells.胰岛素及胰岛素样生长因子信号通路在癌症干细胞中的新作用。
Front Endocrinol (Lausanne). 2014 Feb 4;5:10. doi: 10.3389/fendo.2014.00010. eCollection 2014.
8
The changing role of beta-blocker therapy in patients with cirrhosis.肝硬化患者β受体阻滞剂治疗作用的变化。
J Hepatol. 2014 Mar;60(3):643-53. doi: 10.1016/j.jhep.2013.09.016. Epub 2013 Sep 26.
9
Safety, tolerability, pharmacokinetics and pharmacodynamics following 4 weeks' treatment with empagliflozin once daily in patients with type 2 diabetes.在 2 型糖尿病患者中，每日一次给予恩格列净治疗 4 周后的安全性、耐受性、药代动力学和药效学。
Diabetes Obes Metab. 2013 Jul;15(7):613-21. doi: 10.1111/dom.12073. Epub 2013 Feb 17.
10
Influence of hepatic impairment on the pharmacokinetics and safety profile of dapagliflozin: an open-label, parallel-group, single-dose study.肝功能损害对达格列净药代动力学和安全性特征的影响：一项开放标签、平行组、单次给药研究。
Clin Ther. 2011 Nov;33(11):1798-808. doi: 10.1016/j.clinthera.2011.09.011. Epub 2011 Oct 26.
Zotero 插件